Search for a trial

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

The primary objective of this study is to assess whether the efficacy of ocrelizumab given as two dose regimens of 600 mg (given as 300 mg infusions on days 1 and 15 and 600 mg infusion in the following cycles) or 400 mg (given as 200 mg infusions…

A Two-Stage Phase 1 Repeat Dose Study of BaroFeron* (Recombinant Human Interferon beta-1b) Compared to Betaferon® for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration in Healthy Volunteers

Study Stage 1:To evaluate the safety and tolerability of BaroFeron administered subcutaneously (SC)To determine the PK and PD profiles of BaroFeron administered SC and compare to Betaferon administered SCTo evaluate evidence of activity of BaroFeron…

Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial.

This study has been transitioned to CTIS with ID 2023-505483-11-00 check the CTIS register for the current data. To investigate if early transition to oral treatment after two weeks or longer of IV antibiotic therapy is non-inferior to standard six…

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Primary• To evaluate the effect of ravulizumab on adjudicated On-Trial Relapses in adult patients with NMOSDSecondary• To evaluate the safety of ravulizumab in adult patients with NMOSD• To evaluate the effect of ravulizumab on adjudicated…